cardiomyopathy

Derenofylline is a selective and potent adenosine A(1) antagonist in vitro (Ki=1 nM)

Indecainide (Ricainid) is a novel antiarrhythmic compound that is carcinogenic and can be used to study chronic stable ventricular arrhythmias secondary to coronary artery disease or cardiomyopathy.

Emprumapimod (PF-07265803) is an orally active and specific inhibitor of mitogen-activated protein kinase p38α MAPK, inhibits LPS-induced production of IL-6, and can be used to study dilated cardiomyopathy induced by the LMNA gene.

Norepinephrine bitartrate monohydrate is an effective adrenergic receptor (AR) agonist that directly activates α1, α2, and β1 receptors, and is commonly used to induce cardiomyopathy models.

Norepinephrine is an alkaloid neurotransmitter and an effective adrenergic receptor (AR) agonist that activates α1, α2, and β1 receptors. It is commonly used as a vasoactive agent for the treatment of shock and can also be used to induce cardiomyopathy models.

TUN-92046 (Dimethyl 2-oxoglutarate) is a membrane-permeable alpha-ketoglutarate analogue that inhibits maladaptive autophagy in pressure overloading induced cardiomyopathy.

Fropofol (2-fluoro-1,3-diisopropylbenzene) is a non-anesthetic small molecule that specifically reduces myocardial contractility and inhibits myofilament contraction. It can be used in research on hypertrophic cardiomyopathy and cardiovascular diseases.

EpoY (SD-142) is an irreversible inhibitor of the primary brain microtubule-associated tyrosine carboxypeptidase (TCP), a complex formed by vasohibin-1 (VASH1) and small vasohibin-binding protein (SVBP). By inhibiting TCP with an IC50 value of approximately 500 nM, EpoY effectively reduces the levels of detyrosinated α-tubulin, which is crucial for microtubule dynamics and neuronal differentiation. This inhibition results in significant differentiation defects and is linked to potential issues related to cancer and cardiomyopathy.

Noradrenaline tartrate is an effective adrenergic receptor agonist that activates α1, α2, and β1 receptors. It is a precursor of epinephrine and serves as the principal neurotransmitter of most postganglionic sympathetic fibers and the diffuse projection system in the brain originating from the locus coeruleus, and can be used to establish cardiomyopathy models.

Delocamten is an inhibitor of cardiac myosin, with an IC50 value of 1.1 μM. It is useful in research on hypertrophic cardiomyopathy, left ventricular hypertrophy, and diastolic dysfunction.

RA306 is an orally active CAMK2 inhibitor that effectively disrupts the PEAK1/CAMK2 signaling pathway. It demonstrates anti-tumor activity by inhibiting proliferation, migration, and invasion of breast cancer cells. Additionally, RA306 shows potential in cardiac disease research, as it improves dilated cardiomyopathy in mice.

C2 Ceramide (d14:1 2:0) is a bioactive sphingolipid that, when administered dietarily at 100 μM, induces lipotoxic cardiomyopathy by increasing diastolic and systolic diameter, reducing fractional shortening, and decreasing the number of normal cardiac contractile events in Drosophila.

Norepinephrine hydrochloride is a β1-selective adrenergic receptor agonist with an EC₅₀ of 5.37 μM and can be used to induce cardiomyopathy models.

Cibenzoline is an antiarrhythmic agent that inhibits the KATP channel by directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline shows little anticholinergic activity. Cibenzoline markedly reduces LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for hypertrophic obstructive cardiomyopathy research[1][2].

VO-OHPic is a reversible, noncompetitive, and selective inhibitor of PTEN with an IC50 of 46 nM, effectively attenuating apoptosis, adverse cardiac remodeling, and the presence of pro-inflammatory M1 macrophages in models of doxorubicin-induced cardiomyopathy. Additionally, VO-OHPic inhibits autophagy [1] [2] [3].

CCG-273463 is a potent, covalent, selective inhibitor of GRK5 (IC50: 9 nM). CCG-273463 can be used to study heart failure, hypertrophic cardiomyopathy and cancer.

JB062 is a chemical compound acting as a nonmuscle myosin inhibitor, exhibiting IC50 values of 1.6, 5.4, and >100 μM against skeletal muscle myosin, cardiac muscle myosin, and smooth muscle myosin II, respectively. It selectively exhibits cytotoxicity towards human cancer cells without affecting normal cells. The compound is applicable in research fields concerning muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

JB002, a myosin II inhibitor, exhibits potent activity with an IC50 of ≤10 μM. It holds potential for research applications in muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.

FT011, a direct anti-fibrotic agent,attenuates cardiac remodelling and dysfunction in experimental diabetic cardiomyopathy.

Vasomera, a stable, long-acting vasoactive intestinal peptide (VIP) agonist, targets G-protein-coupled VPAC2 receptors and is employed in the study of cardiomyopathy associated with dystrophinopathies [1].

Visnagin has acute hypotensive, anti-inflammatory, and neuroprotective effects, it protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.

Aficamten is a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy.

Moracin O shows significant neuroprotective, and analgesic activities, it also has a strong protective influence against doxorubicin-induced cardiomyopathy in H9c2 cells with the EC50 value of 4.5 ± 1.3 μM. Moracin O exhibits potent in vitro inhibitory ac

Regaloside C, a glycerol glucoside isolated from the Lilium genus, exhibits notable anti-inflammatory properties.